Tirzepatide and a rash: one case report

A case report published in JAAD Case Reports on 12 June 2026 describes a 55-year-old man with type 2 diabetes who developed a widespread itchy rash after about a year on tirzepatide, and whose skin cleared only once the drug was stopped^[1]. That is one patient. Worth saying plainly at the top, because a single case report is the weakest form of clinical evidence there is, and this one is already being read as though it tells you something about how likely a rash is on tirzepatide. It does not.

What the report describes

The patient had type 2 diabetes and had been taking lisinopril long term alongside tirzepatide. He presented with a diffuse itchy eruption of red, scaly papules across the trunk and limbs, affecting the back, chest and legs. The timing is the part the authors dwell on: the rash appeared after more than a year of continuous treatment, not in the first weeks^[2].

Sequential skin biopsies were taken as the picture evolved. The final one showed eosinophil-rich spongiotic dermatitis with a superficial and deep perivascular lymphocytic infiltrate and scattered dermal eosinophils, a pattern consistent with a delayed, T-cell-mediated drug reaction rather than an immediate allergic one. Direct immunofluorescence was negative for bullous pemphigoid, which matters because bullous pemphigoid has its own reported association with the GLP-1 drug class^[2].

The treatment sequence is the strongest part of the case

While the patient stayed on tirzepatide, his clinicians worked through topical corticosteroids, oral doxycycline, prednisone tapers, methotrexate and dupilumab. None of it held. After tirzepatide was stopped, the eruption resolved completely, with only a short prednisone taper and continued topical steroids alongside^[2].

That sequence is what clinicians call a positive dechallenge: remove the suspected drug, the problem goes away. It is genuine evidence, and the fact that several serious immunosuppressants failed while the drug continued makes the drug a more convincing culprit than it would otherwise be. What is missing is a rechallenge. Nobody restarted tirzepatide to see whether the rash came back, which is the right call clinically and a real gap evidentially.

Why one case cannot give you a risk number

A case report has no denominator. It tells you a thing happened once, to one person, in one clinic. It cannot tell you how often it happens, who is more likely to get it, or whether the rate is higher than you would see in a comparable group not taking the drug. Anyone converting this report into a statement about the skin risk of tirzepatide is inventing a number that the study design cannot produce.

There is also a specific confounder in this case. The patient was on lisinopril, an ACE inhibitor, long term. Long-standing medications are not usually the first suspect for a new rash, and the dechallenge points at tirzepatide, but a second drug in the picture is a second explanation that cannot be formally excluded from one patient. The authors themselves do not claim this is the first such case. They note that only two morbilliform eruptions had previously been reported in this drug class, both linked to dulaglutide, and position their case as an addition to a thin literature rather than a discovery.

What the label and the wider literature already say

Skin and hypersensitivity reactions are not new territory for this drug. The US prescribing information for Mounjaro reports hypersensitivity reactions in 3.2% of tirzepatide-treated patients against 1.7% on placebo in the placebo-controlled trials, describes them as sometimes severe including urticaria and eczema, and carries a warning that serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported. Injection-site reactions ran 3.2% against 0.4% on placebo, and patients who developed anti-tirzepatide antibodies had higher rates of both^[3].

The case authors put the SURPASS hypersensitivity figure at roughly 1% to 2%, all mild to moderate and none leading to discontinuation^[2]. That is a lower number than the label's, and the two are counting from different pools of trials. If you want the figure with a defined denominator behind it, use the label^[3].

The review literature is thin in the same way. A 2024 review in Archives of Dermatological Research catalogued the rare cutaneous reactions reported with GLP-1 agonists, including dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid and morbilliform drug eruptions, drawing almost entirely on case reports and small case series^[4]. A 2026 review in Anais Brasileiros de Dermatologia looking specifically at tirzepatide in dermatology, with a literature search running to May 2025, reached the same place: hypersensitivity and injection-site reactions are documented, severe events are rare, and the evidence base is case reports and small studies^[5]. Neither gives a reliable incidence for morbilliform eruption on tirzepatide specifically, because nobody has measured it.

What this is actually useful for

One thing, mainly: latency. The clinical habit with drug eruptions is to suspect a medicine started in the last few weeks. This patient had been on tirzepatide for over a year. The authors' recommendation is that clinicians consider a drug-induced eruption in patients presenting with generalised rashes while on GLP-1 pathway therapies even after long exposure, because hypersensitivity reactions can turn up with variable latency^[2]. That is a reasonable inference to draw from one well-documented case, and it is a much smaller claim than a risk estimate.

If you are on tirzepatide or semaglutide and a rash appears, the useful move is to tell your prescriber and let them work the differential, including everything else you take. Stopping a prescribed diabetes or weight-management medicine on your own carries its own risks, and one case report is not a reason to. Country-by-country prescribing status is on the tirzepatide regulation pages.